Antibiotic Resistance Scout
Discovery Lens
C Combination Innovation
Two separate worlds finally connect — and the intersection is a product
One-Liner
An AI platform for infectious disease clinicians that takes a bacterial resistance profile as input and outputs computationally predicted drug repurposing candidates, synergistic combinations, and phage therapy matches.
Kill Reason
Clinical decision support software for prescribing decisions requires FDA SaMD clearance and EU MDR certification — a multi-year regulatory pathway that would consume all early capital before a single hospital can legally act on the output. The phage therapy matching component relies on a therapeutic category with no approved products in the US or EU, making that differentiator commercially premature by at least five years.
What do you think?
Related ideas you can explore free:
killed: Urine and stool analysis for glucose monitoring, cancer screening, and kidney function markers falls squarely into FDA Class II/III medical device territory, requiring clinical trials and 510(k) or PMA approval costing millions and taking years. The entire high-value use case — the reason anyone would buy this — is legally undeliverable without regulatory clearance the product cannot realistically obtain.
killed: Amazon Alexa Together and comparable remote family monitoring services already serve this exact use case at consumer price points with embedded distribution advantages that a standalone WiFi sensing module cannot overcome. Daily routine monitoring and anomaly alerting for elderly relatives is a feature, not a product, in the current competitive landscape.
killed: Personal injury narrative reports require specific medico-legal structure, but the format is well-documented in public templates and any chiropractor with a configured AI prompt can replicate the output — there is no proprietary data asset, workflow lock-in, or network effect to justify a subscription fee against a commodity capability.